Remicade Biosimilar Global Market Report 2024: Key Players, Demand Patterns And Forecasts 2033

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Remicade Biosimilar Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The remicade biosimilar market size has grown exponentially in recent years. It will grow from $3.2 billion in 2023 to $3.99 billion in 2024 at a compound annual growth rate (CAGR) of 24.4%. The growth in the historic period can be attributed to introduction of remicade (infliximab), biotechnology advancements, biologics patent expiry, regulatory pathway establishment, healthcare cost pressures.

The remicade biosimilar market size is expected to see exponential growth in the next few years. It will grow to $9.1 billion in 2028 at a compound annual growth rate (CAGR) of 22.9%. The growth in the forecast period can be attributed to patent expirations, rising demand for cost-effective therapies, biosimilar pipeline development, reimbursement policies, market consolidation. Major trends in the forecast period include physician prescribing behavior, biosimilar lifecycle management, biosimilar naming conventions, biosimilar interchangeability, biosimilar real-world evidence.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

Market Segmentation:
The remicade biosimilar market covered in this report is segmented -

1) By Type: 100mg/10ml, 500mg/50ml
2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis, Plaque Psoriasis
3) By Application: Blood Disorders, Oncology Diseases

Major Driver - Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth
The rise in the incidence of autoimmune diseases is expected to propel the growth of the remicade biosimilar market going forward. Autoimmune diseases are disorders in which the immune system mistakenly attacks and damages the body's tissues and organs. Remicade biosimilars are used in treating autoimmune diseases by providing an effective therapeutic option to manage the symptoms and reduce inflammation associated with these. For instance, in October 2021, according to the reports shared by the City University of London, a UK-based public university, in the UK, 7%, or 4 million people, were suffering from autoimmune diseases by 2021, and over 80 autoimmune illnesses were identified with increasing prevalence annually by 3-9%. Furthermore, in July 2021, according to the Cleveland Clinic, a US-based, non-profit academic medical center, autoimmune diseases affected 1 in 15 people, with 1.4 million individuals having Crohn's disease or ulcerative colitis, while 1 million people had lupus in 2021. Therefore, the rise in the incidence of autoimmune diseases is driving the growth of the Remicade biosimilar market.

Competitive Landscape:
Major companies operating in the remicade biosimilar market report are AbbVie Inc., Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Organon & Co., Merck And Co. Inc., Janssen Biotech Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvogen Inc, Synthon International Holding B.V., Coherus Biosciences Inc, Cardinal Health Inc, Genentech Inc., Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Top Trend - Innovative Biosimilar Launches Shape Remicade Market Landscape
Product innovation is a key trend gaining popularity in the Remicade biosimilar market. Major companies operating in the Remicade biosimilar market are developing innovative products to sustain their position in the market. For instance, in January 2023, Amgen Inc, a US-based biotechnology company, launched Amjevita, a biosimilar version of AbbVie's Humira, in the US, designed to be as safe and effective as the original drug. Amjevita is the first biosimilar to Humira and is expected to compete with Humira for market share. It is a biological drug used to treat various autoimmune diseases, including rheumatoid arthritis and Crohn's disease. It is one of the most expensive drugs in the world, generating billions of dollars in sales for AbbVie each year. Amjevita is expected to cost significantly less. In addition to saving money, Amjevita can also offer patients more treatment options.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Remicade Biosimilar Market Characteristics
3. Remicade Biosimilar Market Trends And Strategies
4. Remicade Biosimilar Market - Macro Economic Scenario
5. Remicade Biosimilar Market Size And Growth
…..
27. Remicade Biosimilar Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.